Bachem (OTCMKTS:BCHMF) Trading Up 29.5% – Still a Buy?

Bachem Holding AG (OTCMKTS:BCHMF)’s share price rose 29.5% on Thursday . The company traded as high as $82.73 and last traded at $82.73. Approximately 100 shares were traded during trading, an increase of 0% from the average daily volume of 100 shares. The stock had previously closed at $63.87.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BCHMF shares. Deutsche Bank Aktiengesellschaft upgraded Bachem to a “buy” rating in a research report on Monday, October 27th. UBS Group raised Bachem to a “buy” rating in a report on Tuesday, December 2nd. Finally, Jefferies Financial Group assumed coverage on Bachem in a report on Thursday, September 25th. They set an “underperform” rating for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Bachem Price Performance

The business’s 50-day simple moving average is $62.45 and its 200-day simple moving average is $63.99.

Bachem Company Profile

Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases.

Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies.